USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about capreomycin. Some of the dosage forms listed on this page may not apply to the brand name Capastat Sulfate.
Applies to capreomycin: injection powder for solution
Injection route (Powder for Solution)
Use capreomycin in patients with renal insufficiency or preexisting auditory impairment with great caution, and the risk of additional auditory impairment or renal injury should be weighed against the benefits to be derived from therapy. Simultaneous administration of other parenteral antituberculosis agents which have similar and sometimes irreversible toxic effects, particularly on auditory and renal function, is not recommended. Use with nonantituberculosis drugs having ototoxic or nephrotoxic potential should be undertaken only with great caution. The safety of capreomycin in pregnancy and in pediatric patients has not been established.
Along with its needed effects, capreomycin (the active ingredient contained in Capastat Sulfate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking capreomycin:
Incidence not known
Some side effects of capreomycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to capreomycin: intramuscular powder for injection
The most commonly reported side effects included blood urea nitrogen (BUN) elevations above 20 mg/100 mL, subclinical hearing loss, and eosinophilia.
A fatal case of renal insufficiency and oliguria occurred in a patient with tuberculosis and portal cirrhosis treated with 1 g of this drug and aminosalicylic acid daily for 1 month. Toxic nephritis was reported, and autopsy showed subsiding acute tubular necrosis.
Very common (10% or more): BUN elevation above 20 mg/100 mL (up to 26%)
Common (1% to 10%): BUN elevation above 30 mg/100 mL
Frequency not reported: Acute tubular necrosis, depression of phenolsulfonphthalein (PSP) excretion, oliguria, renal insufficiency, toxic nephritis
Very common (10% or more): Subclinical auditory loss (up to 11%)
Common (1% to 10%): Clinically apparent hearing loss
Frequency not reported: Death, febrile reaction, ototoxicity, tinnitus
Rare (0.01% to 0.1%): Thrombocytopenia
Frequency not reported: Eosinophilia, leukocytosis, leukopenia
Frequency not reported: Excessive bleeding at injection site, injection site induration, injection site pain, sterile abscesses
Frequency not reported: Electrolyte disturbances, hypocalcemia, hypokalemia, hypomagnesemia
Frequency not reported: Abnormal liver function tests, decrease in bromsulphalein (BSP) excretion
Frequency not reported: Maculopapular skin rashes, urticaria
Frequency not reported: Vertigo
Frequency not reported: Abnormal urine sediment
June 26, 2020
June 25, 2020
June 27, 2020
July 10, 2020
July 9, 2020
July 1, 2020